Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
combining its DecisionDx-UM test with PRAME gene expression more accurately predicts metastasis-free and overall survival than next-generation sequencing-based mutation analysis alone. This work underscores how gene expression profiling that captures signals from both tumor and immune cells may offer more clinically actionable risk stratification than mutation-only approaches. Next, we'll explore how this new evidence supporting DecisionDx-UM plus PRAME could influence Castle Biosciences' broader investment narrative and growth outlook. Uncover the next big thing with financially sound penny stocks that balance risk and reward To own Castle Biosciences, you need to believe its molecular diagnostics can keep earning clinical trust and reimbursement despite rising payer scrutiny and competition. The new DecisionDx-UM plus PRAME data strengthens the company's clinical story, but does not directly ease the immediate reimbursement overhang from the noncoverage policy affecting Deci
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal MelanomaGlobeNewswire
- Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]Yahoo! Finance
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal CancerGlobeNewswire
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 12/17/25 - Form 144
- 12/17/25 - Form 4
- 12/15/25 - Form 144
- CSTL's page on the SEC website